High proportion of mutant osteoblasts is compatible with normal skeletal function in mosaic carriers of osteogenesis imperfecta.
about
Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfectaThe Expansion of mtDNA Haplogroup L3 within and out of AfricaEhlers-Danlos arthrochalasia type (VIIA-B)--expanding the phenotype: from prenatal life through adulthood.Potential implications of cell therapy for osteogenesis imperfecta.Current and emerging treatments for the management of osteogenesis imperfecta.A scoring system for the assessment of clinical severity in osteogenesis imperfecta.Intrauterine Bone Marrow Transplantation in Osteogenesis Imperfecta Mice Yields Donor Osteoclasts and Osteomacs but Not Osteoblasts.Allele dependent silencing of collagen type I using small interfering RNAs targeting 3'UTR Indels - a novel therapeutic approach in osteogenesis imperfecta.In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta.Asymptomatic parental mosaicism for osteogenesis imperfecta associated with a new splice site mutation in COL1A2.Allele-specific Col1a1 silencing reduces mutant collagen in fibroblasts from Brtl mouse, a model for classical osteogenesis imperfecta.New perspectives on osteogenesis imperfectaTherapeutic application of mesenchymal stem cells in bone and joint diseases.Local transplantation is an effective method for cell delivery in the osteogenesis imperfecta murine model.Correction of a mineralization defect by overexpression of a wild-type cDNA for COL1A1 in marrow stromal cells (MSCs) from a patient with osteogenesis imperfecta: a strategy for rescuing mutations that produce dominant-negative protein defects.Tissue-specific mosaicism for a lethal osteogenesis imperfecta COL1A1 mutation causes mild OI/EDS overlap syndrome.New frontiers for dominant osteogenesis imperfecta treatment: gene/cellular therapy approachesTreatment options for osteogenesis imperfecta
P2860
Q24298392-1059049E-DCEE-4FA7-A5DA-B60312CF6C15Q28253383-0DF9CB02-823B-45A5-822C-F86CDFDD8090Q33631093-CEE9D959-2382-4DCC-A014-FE417C40F03AQ33863266-A75498E4-EC91-4DEF-BFAB-23587F2F0E22Q34133308-A9457C09-13FB-4110-B315-2A805D367C5DQ35828159-3D3EC783-B1C3-4B6B-A799-7106F8EB1483Q36290920-BB63E629-893A-4701-9888-316992F1B352Q37119320-980B0AA7-31DC-49B2-94F6-125A70DDCED6Q37271063-D21DBFDC-22D5-4DA1-8241-69994816A6F6Q37319354-FDAC5F22-A931-4043-9782-12565C688302Q37711784-AA5B795F-8985-423C-82D0-B2476BBCB3D9Q37889113-5DD26A24-53DD-44BD-B82F-317E916FDDD9Q38057676-CE46F07A-B046-4E06-9653-638311BE6016Q42062735-3B43165C-5684-4D96-9422-35382528FB01Q45882623-8B205602-EF29-4835-BCE4-41D4076CFBEDQ52896254-41043E3C-F624-408B-A8EA-F92F51F4C397Q58270335-F35EF048-FAB1-4184-80FC-30082244B5FBQ58752199-50411C19-DBA5-4AA8-8713-D22226ADCAB5
P2860
High proportion of mutant osteoblasts is compatible with normal skeletal function in mosaic carriers of osteogenesis imperfecta.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
High proportion of mutant oste ...... rs of osteogenesis imperfecta.
@ast
High proportion of mutant oste ...... rs of osteogenesis imperfecta.
@en
type
label
High proportion of mutant oste ...... rs of osteogenesis imperfecta.
@ast
High proportion of mutant oste ...... rs of osteogenesis imperfecta.
@en
prefLabel
High proportion of mutant oste ...... rs of osteogenesis imperfecta.
@ast
High proportion of mutant oste ...... rs of osteogenesis imperfecta.
@en
P2860
P356
P1476
High proportion of mutant oste ...... rs of osteogenesis imperfecta.
@en
P2093
Joan C Marini
Wayne A Cabral
P2860
P304
P356
10.1086/383252
P407
P577
2004-03-11T00:00:00Z